Kevin Wysocki, President of ProPharma Group, Clinical Research Solutions Division
Amidst an innovation boom and a growing number of startups in recent years, the biotech industry has prospered with a slew of mergers and acquisitions. As the larger contract research organizations (CRO) that are the nexus of highly skilled drug R&D specialists started acquiring all the nimble players in the industry, particularly during the pandemic, it left a huge talent crisis in the biotech sphere. A majority of biotech startups that had become heavily reliant on the bigger pharma companies found themselves in a crunch, often failing to get priority from the larger CRO partners because of lesser funding. This brought about the need for a CRO with end-to-end services that are not only customizable and tailored to a company’s needs but are also scalable on a global level.
ProPharma Group, a leading global, independent, single-source provider of regulatory, clinical, and compliance services, is perfectly positioned to bridge that gap. ProPharma Group’s multiple service lines, namely regulatory sciences, clinical research solutions, medical information, and pharmacovigilance (PV), uniquely position the company to be able to service customers throughout the entire lifecycle of their products and therapies. Once the products and therapies are on the market, ProPharma Group can support customers from a post-marketing safety and medical information perspective as well. “Few organizations have such unique disparate yet complementary service lines operating under one banner as ProPharma Group,” says Kevin Wysocki, President of ProPharma Group, Clinical Research Solutions (CRS) Division.
From the get-go, ProPharma Group aims to be an extension of their client’s internal team. “We believe not everything is one size fits all, our service is more fit for purpose,” says Brittany Strubbe, Vice President of Business Development for ProPharma Group, CRS Division. As the CRS team of ProPharma Group uncovers and qualifies an opportunity with a client, they engage their functional leadership team along with business development representatives at the customer level.
Wysocki expresses that each of their functional leaders works toward the success of every project they take on. ProPharma Group takes every issue that arises in a clinical trial extremely seriously, generating and implementing a plan accordingly to overcome that problem. “Allowing our sponsors to see our team engage with the functional issues provides them with a level of comfort as the trial goes through its execution,” says Wysocki.
ProPharma Group stands by its goal of improving patient health and safety while doing right by its sponsors. “Because of the depth and breadth of our subject matter expertise across all of our service lines, we have the luxury to customize the right team according to the needs of the sponsor,” says Brittany Strubbe, Vice President of Business Development, Clinical Research Solutions Division, ProPharma Group.
Extremely mindful of their client’s goals, ProPharma Group adopts an innovative, collaborative, and forwardlooking approach versus a responsive and reactive one. Case in point, Brittany mentions how their team’s foresight and services helped support one of their sponsors in their clinical studies, enabling them to become a commercial organization. The sponsor was moving into pivotal studies extremely quickly, but they weren’t equipped to do so as they were not a commercial organization yet. Having already worked with them on smaller projects, ProPharma Group performed a full risk profile on what they were going to be up against within the next 12 months. With this early assessment, their functional leadership team and sales team had the foresight to suggest a customizable functional service provision (FSP) based on the sponsor’s needs. This multi-function FSP helped provide extensions to the sponsor company’s internal team and bolstered the team as they moved into pivotal studies while becoming a commercial organization.
Few organizations have such unique disparate yet connected service lines operating under one
banner as ProPharma Group
With a strong foothold in the U.S., ProPharma Group has imminent plans of expanding their business into the European and Asia Pacific regions, particularly for their CRS division. Toward the second quarter of this year, the organization aims to enable a more patient-centric approach to clinical trial execution rather than the traditional sitecentric approach. Their decentralized clinical trial service will focus primarily on remote in-home nurses coupled with a customized, enabling technology that allows remote data capture. Also, in line with the digital transformation trend, ProPharma Group is revamping its services from a technological standpoint. “With everything moving toward automation, we are on our way to leverage that to make drug development more efficient,” Brittany concludes.